Results 1 to 10 of about 555,062 (342)

Acute lymphoblastic leukemia [PDF]

Pediatric Blood & Cancer, 2021
The survival of patients with acute lymphoblastic leukemia (ALL) has improved significantly with the use of intensive multimodality treatment regimens including chemotherapy, high‐dose chemotherapy and stem cell rescue, and radiation therapy when ...
John Han-Chih Chang, M. Poppe, Chia-Ho Hua, K. Marcus, N. Esiashvili   +4 more
semanticscholar   +3 more sources

Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2021
The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for ...
P. Brown, B. Shah, A. Advani, P. Aoun, M. Boyer, P. Burke, D. DeAngelo, S. Dinner, A. Fathi, J. Gauthier, N. Jain, Suzanne Kirby, M. Liedtke, M. Litzow, A. Logan, S. Luger, L. Maness, S. Massaro, R. Mattison, William May, O. Oluwole, Jae H. Park, Amanda C. Przespolewski, S. Rangaraju, J. Rubnitz, G. Uy, M. Vusirikala, M. Wieduwilt, B. Lynn, R. Berardi, Deborah A. Freedman-Cass, Mallory Campbell   +31 more
semanticscholar   +1 more source

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.

Cancer Discovery, 2021
Combining venetoclax, a selective BCL-2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL-2 inhibitor, may allow targeting of both BCL-2 and BCL XL without dose-limiting thrombocytopenia associated with navitoclax monotherapy.
V. Pullarkat, Norman J. Lacayo, E. Jabbour, J. Rubnitz, A. Bajel, T. Laetsch, Jessica T. Leonard, Susan I. Colace, S. Khaw, S. Fleming, R. Mattison, R. Norris, J. Opferman, K. Roberts, Yaqi Zhao, Chunxu Qu, Mohamed Badawi, Michelle Schmidt, Bo Tong, John C. Pesko, Yan Sun, J. Ross, D. Vishwamitra, Lindsey Rosenwinkel, S. Y. Kim, A. Jacobson, C. Mullighan, Thomas B. Alexander, W. Stock   +28 more
semanticscholar   +1 more source

Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia

Journal of Clinical Medicine, 2021
The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably during the last five decades. Such improvements were made possible by the incorporation of new diagnostic technologies, the effective administration of conventional ...
H. Inaba, C. Pui
semanticscholar   +1 more source

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. [PDF]

PLoS ONE, 2015
Osteonecrosis is one of the most common, serious, toxicities resulting from the treatment of acute lymphoblastic leukemia. In recent years, pediatric acute lymphoblastic leukemia clinical trials have used discontinuous rather than continuous dosing of ...
Laura B Ramsey, Laura J Janke, Monique A Payton, Xiangjun Cai, Steven W Paugh, Seth E Karol, Landry Kamdem Kamdem, Cheng Cheng, Richard T Williams, Sima Jeha, Ching-Hon Pui, William E Evans, Mary V Relling   +12 more
doaj   +1 more source

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

New England Journal of Medicine, 2020
BACKGROUND Outcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment.
R. Foà, R. Bassan, A. Vitale, L. Elia, A. Piciocchi, M. Puzzolo, M. Canichella, P. Viero, F. Ferrara, M. Lunghi, F. Fabbiano, M. Bonifacio, N. Fracchiolla, P. Di Bartolomeo, A. Mancino, M. D. De Propris, M. Vignetti, A. Guarini, A. Rambaldi, S. Chiaretti   +19 more
semanticscholar   +1 more source

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

Haematologica, 2019
The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of patients with acute lymphoblastic leukemia/lymphoma and assessed the in vitro impact ...
Evgeniya Angelova, Charlene Audette, Yelena Kovtun, Naval Daver, Sa A. Wang, Sherry Pierce, Sergej N. Konoplev, Haitham Khogeer, Jeffrey L. Jorgensen, Marina Konopleva, Patrick A. Zweidler-McKay, L. Jeffrey Medeiros, Hagop M. Kantarjian, Elias J. Jabbour, Joseph D. Khoury   +14 more
doaj   +1 more source

Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

New England Journal of Medicine, 2018
Background In a single‐center phase 1–2a study, the anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and ...
S. Maude, T. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. Verneris, H. Stefanski, G. D. Myers, M. Qayed, B. De Moerloose, H. Hiramatsu, Krysta D Schlis, K. Davis, P. Martin, Eneida R. Nemecek, G. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C. June, B. Levine, P. Wood, T. Taran, M. Leung, K. Mueller, Yiyun Zhang, K. Sen, D. Lebwohl, M. Pulsipher, S. Grupp   +34 more
semanticscholar   +1 more source

Oral health management in children with acute lymphoblastic leukemia

口腔疾病防治, 2021
Acute lymphoblastic leukemia is the most common type of leukemia in children. In recent years, the treatment and prognosis of acute lymphoblastic leukemia in children have improved significantly. However, acute lymphoblastic leukemia itself and treatment
TANG Yawen, ZHANG Lin, YANG Xue, ZOU Jing, WANG Yan   +4 more
doaj   +1 more source

Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia

Haematologica, 2011
Acute lymphoblastic leukemia is the major pediatric cancer in developed countries. To date most association studies of acute lymphoblastic leukemia have been based on the candidate gene approach and have evaluated a restricted number of polymorphisms ...
Amy L. Sherborne, Kari Hemminki, Rajiv Kumar, Claus R. Bartram, Martin Stanulla, Martin Schrappe, Eleni Petridou, Ágnes F. Semsei, Csaba Szalai, Daniel Sinnett, Maja Krajinovic, Jasmine Healy, Marina Lanciotti, Carlo Dufour, Stefania Indaco, Eman A El-Ghouroury, Ruchchadol Sawangpanich, Suradej Hongeng, Samart Pakakasama, Anna Gonzalez-Neira, Evelia L. Ugarte, Valeria P. Leal, Juan P.M. Espinoza, Azza M. Kamel, Gamal T.A. Ebid, Eman R. Radwan, Serap Yalin, Erdinc Yalin, Mehmet Berkoz, Jill Simpson, Eve Roman, Tracy Lightfoot, Fay J. Hosking, Jayaram Vijayakrishnan, Mel Greaves, Richard S. Houlston   +35 more
doaj   +1 more source